MAPK1 and lung adenocarcinoma: A study reported that circASK1 expression was decreased in gefitinib‐resistant lung adenocarcinoma cells and that its reduced expression played a role in enhancing the gefitinib sensitivity of lung adenocarcinoma cells by activating the ASK1/JUK/p38 signalling pathway mediated through the encoded protein ASK‐272aa.